Emcure Pharmaceuticals Share News - Latest Updates, Live News & More

Latest news about Emcure Pharmaceuticals

Emcure Pharma: Co Says Gujarat Facility Receives 'No Action Indicated' From US FDA 10 days ago

Emcure Pharmaceuticals has received a No Action Indicated (NAI) classification from the USFDA for its manufacturing facility in Kadu, Gujarat. This favorable regulatory outcome indicates that the facility met all required standards during the inspection, strengthening the company's manufacturing capabilities and compliance status for regulated market access.

Emcure Launches Poviztra® Weight Control Drug in Five Strengths Across India Dec 22, 2025

Emcure Pharmaceuticals Allots 7,700 Equity Shares Under Employee Stock Option Scheme Dec 16, 2025

Emcure Pharmaceuticals' Company Secretary Chetan Sharma Steps Down Nov 21, 2025

Emcure Pharmaceuticals Secures Stock Exchange Approval for Promoter Group Reclassification Nov 18, 2025

More news about Emcure Pharmaceuticals

17Nov 25

Emcure Pharmaceuticals Reports Strong Q2 Growth and Announces Strategic Partnership with Novo Nordisk

Emcure Pharmaceuticals reported robust Q2 financial results with 13% YoY revenue growth to INR 2,270.00 crores and 25% PAT growth to INR 251.00 crores. Domestic business grew 10.6% to INR 1,031.00 crores, while international markets grew 15.8% to INR 1,238.00 crores. The company announced an exclusive partnership with Novo Nordisk to launch Poviztra (semaglutide) for obesity treatment in India, targeting an estimated 250 million obese/overweight population. Emcure aims to expand in chronic disease segments, leverage partnerships, invest in R&D, and explore M&A opportunities.

11Nov 25

Emcure Pharmaceuticals Posts Strong Q2 Results with 13.4% Revenue Growth

Emcure Pharmaceuticals announced robust Q2 financial results, with revenue from operations increasing 13.4% year-on-year to ₹2,270 crore. EBITDA grew 15.2% to ₹439 crore, and Profit After Tax rose 24.7% to ₹251 crore. The company saw growth in both domestic (10.6%) and international (15.8%) markets. Emcure partnered with Novo Nordisk to launch Poviztra, a biological injectable for weight management, in India. The company also acquired the remaining stake in its subsidiary, Zuventus Healthcare Ltd.

10Nov 25

Emcure Pharmaceuticals Partners with Novo Nordisk India for Weight Loss Drug Distribution

Emcure Pharmaceuticals has secured exclusive distribution rights for Povitra® (semaglutide injection 2.4 mg), a second brand of the weight loss drug Wegovy®, in India through a strategic partnership with Novo Nordisk India. This collaboration aims to expand access to innovative weight management solutions across the country. Emcure will leverage its marketing and distribution capabilities to improve accessibility, particularly in regions beyond Novo Nordisk's current reach. The partnership addresses India's significant obesity challenge, with 254 million people affected by generalized obesity and 351 million by abdominal obesity.

10Oct 25

Emcure Pharmaceuticals Receives Clean Bill from FDA for Kadu Facility

Emcure Pharmaceuticals' manufacturing facility in Kadu, Gujarat, has successfully passed a United States Food and Drug Administration (FDA) surveillance inspection without any observations. The company has officially informed the National Stock Exchange of India Limited and BSE Limited about this development. This clean bill from the FDA demonstrates Emcure's regulatory compliance, quality assurance, and could potentially lead to increased export opportunities to the US market.

03Oct 25

Emcure Pharma Completes Full Ownership of Zuventus Healthcare

Emcure Pharmaceuticals has completed the acquisition of the remaining 20.42% stake in Zuventus Healthcare Limited for Rs. 7,249.00 million, making it a wholly-owned subsidiary. The transaction involved purchasing 4,095,180 equity shares, increasing Emcure's ownership from 79.58% to 100%. The acquisition was approved on June 21, 2025, and completed by October 3, 2025. Zuventus Healthcare, incorporated in 2002, deals in pharmaceutical medicaments and reported a turnover of Rs. 10,798.99 million and a PAT of Rs. 1,347.82 million for FY 2024-25.

06Sept 25

Emcure Pharmaceuticals Posts Robust Q1FY25 Results with 16.6% Revenue Growth

Emcure Pharmaceuticals announced robust Q1FY25 financial results. Consolidated revenue reached Rs 1,815.00 crore, up 16.6% YoY. EBITDA grew 15.8% to Rs 360.00 crore, with margins at 19.8%. Profit After Tax increased 8.2% to Rs 153.00 crore. Domestic business grew 14% to Rs 909.00 crore, while international operations rose 19.5% to Rs 906.00 crore. North American market showed exceptional 72.3% growth, and Europe grew by 8.6%. The company's partnership with Sanofi for cardiovascular brands boosted domestic performance. Emcure maintains its position as the 12th largest pharmaceutical company in India, operating in over 70 countries globally.

07Aug 25

Emcure Pharmaceuticals Reports Robust Q1 Results with 41% PAT Growth

Emcure Pharmaceuticals announced robust Q1 financial results. Revenue from operations increased by 15.7% to Rs. 2,101.00 crore, EBITDA grew by 20.1% to Rs. 404.00 crore, and PAT surged by 41% to Rs. 215.00 crore. Domestic business sales rose by 9.4%, while international business sales grew by 22.1%. The company expanded its strategic partnership with Sanofi, now marketing Sanofi's Oral Anti-diabetic portfolio alongside the existing cardiovascular portfolio. Management remains focused on improving efficiencies and has a strong product pipeline for future growth.

10Jul 25

Emcure Pharma's Sanand Facility Aces FDA Inspection with Zero Observations

Emcure Pharmaceuticals announced that its Sanand facility successfully passed a pre-approval inspection by the U.S. FDA without any observations. The inspection concluded without the issuance of Form 483, indicating no concerns were identified. This outcome demonstrates Emcure's commitment to quality and compliance with international regulatory standards, potentially expediting approvals for drugs manufactured at the facility for the U.S. market and enhancing the company's reputation in the global pharmaceutical industry.

09Jul 25

EMCURE Pharma's Sanand Facility Passes US FDA Inspection with Flying Colors

Emcure Pharmaceuticals announced the successful completion of a United States Food and Drug Administration (US FDA) inspection at its Sanand facility, with no observations noted. This outcome demonstrates the company's commitment to high-quality manufacturing standards and regulatory compliance. The clean inspection report could enhance Emcure's reputation, strengthen its global market position, and potentially facilitate future drug approvals for the US market.

04Jul 25

Bain Capital Affiliate Offloads 2.4% Stake in Emcure Pharmaceuticals

BC Investments IV, an affiliate of Bain Capital, sold approximately 45.51 lakh shares (2.4% stake) of Emcure Pharmaceuticals in a block deal. The transaction was executed at ₹1,262.00 per share, totaling ₹574.00 crore. The sale price was below the set floor price of ₹1,279.80. Following the news, Emcure's stock price declined by 1.63%.

04Jul 25

Emcure Pharmaceuticals Sees Massive Block Trade Worth Rs. 572.94 Crores

A substantial block trade of 4,534,554 shares of Emcure Pharmaceuticals Ltd. was reported on the National Stock Exchange (NSE). The transaction was executed at Rs. 1,263.50 per share, totaling Rs. 572.94 crores. This significant trade indicates potential shifts in ownership or strategic moves by large institutional investors in the pharmaceutical sector. The identities of the buyer and seller remain undisclosed. The market will be closely watching for any impact on Emcure's stock performance and shareholding pattern in the coming days.

04Jul 25

Emcure Pharmaceuticals: BC Investments to Offload 2.4% Stake in ₹551 Crore Block Deal

BC Investments, backed by Bain Capital, plans to sell a 2.4% stake (45.5 lakh shares) in Emcure Pharmaceuticals through a block deal. The offer price is set at ₹1,225.00 per share, a 4% discount to the current market price, with a total deal size of ₹551.00 crore. Kotak Securities is the book runner for the transaction. Emcure recently reported strong Q4 results with a 63% increase in profit after tax to ₹197.00 crore and a 19.5% rise in revenue to ₹2,116.00 crore.

04Jul 25

Bain Capital to Offload 2.4% Stake in Emcure Pharmaceuticals for ₹551 Crore

BC Investments IV, backed by Bain Capital, plans to sell 2.4% (45.5 lakh shares) of Emcure Pharmaceuticals for ₹551 crore. The offer price is ₹1,225 per share, a 4% discount to the current market price. The block deal, to be executed through Kotak Securities, comes after Emcure reported strong Q4 results with a 63% increase in profit after tax to ₹197 crore and a 19.5% rise in revenue to ₹2,116 crore.

21Jun 25

Emcure Pharmaceuticals to Acquire Remaining Stake in Zuventus Healthcare for ₹724.9 Crore

Emcure Pharmaceuticals announced plans to acquire the remaining 20.42% stake in Zuventus Healthcare Ltd for ₹724.90 crore. This acquisition will make Zuventus Healthcare a wholly owned subsidiary of Emcure. The transaction is expected to close in Q2 FY26, marking a significant move to strengthen Emcure's market position in the Indian pharmaceutical industry.

17Jun 25

Emcure Pharma Expands Operations with New Subsidiary

Emcure Pharmaceuticals has formed a new fully-owned subsidiary named Emcure Lifesciences Private Limited. This strategic move suggests potential growth and diversification plans for the company. While specific details about the new subsidiary's focus are not provided, it could signal intentions for market expansion, product diversification, enhanced R&D capabilities, or improved operational efficiency.

23May 25

Emcure Pharmaceuticals Reports 64% Surge in Q4 Profit, Announces Dividend

Emcure Pharmaceuticals posted a 64% increase in Q4 net profit to Rs 189.00 crore, with revenue rising to Rs 2,116.00 crore. Profit margins expanded to 19%. The company announced a dividend of Rs 3.00 per share and plans to incorporate a wholly-owned subsidiary, Emcure Generics Pvt. Year-over-year, revenue grew by 18.93%, net profit by 62.98%, EBITDA by 22.76%, and EPS increased to Rs 9.97, up 56.76%.

22May 25

Emcure Pharmaceuticals Reports 64% Surge in Q4 Profit, Stock Rises 8%

Emcure Pharmaceuticals Ltd. announced strong Q4 results with a 64% year-on-year increase in net profit to ₹189.00 crore. Revenue grew by 20% to ₹2,116.00 crore, while EBITDA rose by 29.68% to ₹402.00 crore. The company's EBITDA margin improved to 19.01% from 17.54%. Following these results, the board recommended a final dividend of ₹3.00 per share, leading to an 8% increase in stock price.

21Apr 25

Emcure Pharmaceuticals Receives Positive USFDA Inspection Report for API Facility

Emcure Pharmaceuticals has received a positive Establishment Inspection Report (EIR) from the USFDA for its API facility in Kurkumbh, Pune. The facility was classified as 'Voluntary Action Indicated' (VAI), indicating minor issues but overall compliance with USFDA standards. This outcome demonstrates Emcure's regulatory compliance, potentially boosting market confidence and business opportunities, particularly in the U.S. market.

19Apr 25

Emcure Pharmaceuticals Receives USFDA Approval for API Facility

Emcure Pharmaceuticals has received an Establishment Inspection Report (EIR) from the USFDA for its API facility in Kurkumbh, Pune. The facility was classified as 'Voluntary Action Indicated' (VAI), indicating minor objectionable conditions but no serious regulatory concerns. This outcome enhances Emcure's regulatory compliance status and potential for U.S. market access, reflecting positively on their quality control measures and manufacturing processes.

04Apr 25

Emcure's European Arm Tillomed Expands Portfolio with £19.7 Million Acquisition from Manx

Emcure Pharmaceuticals' European subsidiary, Tillomed, has acquired a pharmaceutical portfolio from Manx for £19.7 million (₹206.85 crore). This strategic move aims to expand Tillomed's product offerings and strengthen its position in the European market. The acquisition is expected to enhance Emcure's European presence, potentially leading to increased market share and revenue growth.

01Apr 25

Emcure Pharmaceuticals' Subsidiary Inks Deal to Revolutionize Skin Tightening Market in India

Emcure Pharmaceuticals' subsidiary, Emcutix Biopharmaceuticals, has signed an exclusive agreement with Italian firm WiQo to import and distribute 'PRX-PLUS', an innovative skin tightening product, in India. PRX-PLUS offers immediate, non-invasive skin tightening without injections or recovery time. The Indian dermatology market, valued at $1.80 billion, is expected to grow at 11-12%. This partnership aims to introduce advanced skincare solutions and strengthen Emcure's position in the expanding dermatology sector.

01Apr 25

Gennova Biopharmaceuticals Secures $13.38 Million for AI-Enhanced Nipah Virus Vaccine Development

Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, has expanded its collaboration with CEPI, receiving up to $13.38 million in funding to develop a Nipah virus vaccine. The project will use Gennova's self-amplifying mRNA technology and AI capabilities from Houston Methodist Research Institute. Nipah virus, with a mortality rate of up to 75%, poses a threat to over 2 billion people globally. The partnership aims to ensure equitable access to the developed vaccines and could serve as a model for rapid response to future epidemic threats. Preclinical and phase 1 trials will be conducted in India.

01Apr 25

Emcure Pharmaceuticals' Subsidiary Inks Exclusive Deal with Italian Skincare Brand WIQO

Emcure Pharmaceuticals' subsidiary, Emcutix, has entered an exclusive licensing partnership with Italian derma-cosmetic brand WIQO to introduce innovative skincare solutions in India. This strategic move aims to capitalize on the growing Indian skincare market. Simultaneously, another Emcure subsidiary, Gennova Biopharmaceuticals, is advancing in vaccine development, securing $13.38 million from CEPI to develop a Nipah virus vaccine using saRNA technology.

10Mar 25

Emcure Pharmaceuticals Expands into Daily Supplements Market, Partners with Vidya Balan

Emcure Pharmaceuticals has expanded its Arth range to enter the daily supplements market, focusing on women's health and wellness. The company has partnered with Bollywood actor Vidya Balan as brand ambassador to promote key products including intimate care, sleep support gummies, and brain fog aid. This strategic move aims to address overlooked health concerns and destigmatize women's health issues, potentially opening new revenue streams in the growing wellness sector.

27Feb 25

Emcure Pharmaceuticals Receives Two Observations from USFDA Inspection at API Facility

Emcure Pharmaceuticals' API manufacturing facility in Maharashtra, India, underwent a USFDA inspection from February 19-25, 2025, resulting in two Form 483 observations. The company has committed to addressing these observations comprehensively and responding within the stipulated timeframe. The specific details of the observations were not disclosed in the regulatory filing.

26Feb 25

Emcure Pharmaceuticals Receives Two Observations in FDA Inspection of Pune API Plant

Emcure Pharmaceuticals' API manufacturing facility in Pune underwent a USFDA inspection from February 19-25, 2025, resulting in two observations on Form 483. The company has committed to addressing these observations comprehensively within the stipulated timeframe. The inspection was conducted at the M.I.D.C., Kurkumbh, Taluka - Daund, Pune facility, focusing on current Good Manufacturing Practices (cGMP).